Anti-Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment R58 mAb (Clone 18F9-16)

Cosmo Bio LTD

Catalog No: CAC-RIK-MA-R58

• 
• 

Catalog numbers beginning with "CAC" are antibodies from our exclusive Cosmo Bio Antibody Collection. Visit the CAC Antibody homepage to browse the collection list, organized by research topic.

Click here to browse a well organized list of products for Bone, Collagen, and Extracellular Matrix research.

Background
Anti-Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment R58-specific mAb 18F9-16 was cloned from mice immunized with R58 peptide [CGQILSKLR]. 18F9-16 recognizes the C-terminus cut end of LAP degradation product (LAP-D) R58 produced when latent TGF-β is digested with Plasma Kallikrein. 18F9-16 is validated for IHC and IF.

TGF-β is produced as a pro-protein latent complex in which a 25 kDa active TGF-β fragment is trapped by an N-terminal pro-peptide called Latency Associated Protein (LAP). Active TGF-β is released from the latent complex in a process called the TGF-β activation reaction involving a conformational change induced by binding of the latent complex to cell adhesion proteins such as thrombospondin and integrins, and/or by being cleaved by serine proteases, cysteine proteases, and MMPs in an organ and context-depending manner.

Kojima and his colleagues in the Cellular Molecular Pathology Research Unit (currently, Center for Integrative Medical Sciences, Liver Cancer Prevention Research Unit), RIKEN, Japan focused on the role of serine proteases plasmin and plasma kallikrein in the release and activation of TGF-β and its involvement in liver diseases. They showed that plasmin and plasma kallikrein cleave, respectively, at Lys⁵⁶-Leu⁵⁷ and Arg⁵⁸-Leu⁵⁹ within the LAP portion of the latent TGF-β1 molecule. The anti-TGF-β1 LAP-degradate (LAP-D) antibodies are useful for investigating the molecular mechanism of TGF-β activation and its related diseases, including liver fibrosis/cirrhosis and liver degeneration.

Applications

• Immunohistochemistry (IHC)            10 μg/mL
• Optimal dilutions/concentrations should be determined by the end user.

Specifications

• Host Species               mouse
• Form                           liquid, PBS (pH 7.4), 0.05% NaN3
• Volume                       100 μg (1 mg/mL)
• Specificity                   recognizes C-terminus cut end of LAP degradation product (LAP-D) R58 when latent TGF-β is digested with Plasma Kallikrein (PLK).
• Antigen                       R58 peptide [CGQILSKLR]
• Clonality                     monoclonal (clone # 18F9-16)
• Isotype                        IgG3
• Purification                 purified by affinity column (Protein A) from serum-free cell culture medium
• Conjugation                none
• Storage condition        store below -20°C (below -70°C for prolonged storage) Aliquot to avoid freeze/thaw cycles.

Product Description

Package Size	100 µg
Solution	Liquid, PBS (pH 7.4), 0.05% NaN3
Concentration	1 mg/mL
Purity	Purified from cell culture of serum-free medium by affinity column (Protein G)
Species	Monoclonal Mouse IgG1 clone # 6D6
Immunogen	L59 peptide [LASPPSQGEVPGGC]
Specificity	Recognizes N-terminus cut end of LAP degradates (LAP-D) L59 when latent TGF-β is digested with Plasma Kallikrein (PLK).
Storage	Store below -20°C. Avoid freeze-thaw cycles.

References

• (1)LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis.
  Hara M, Kirita A, Kondo W, Matsuura T, Nagatsuma K, Dohmae N, Ogawa S, Imajoh-Ohmi S, Friedman SL, Rifkin DB, Kojima S.
  Springerplus. 2014 May 1;3:221. doi: 10.1186/2193-1801-3-221. eCollection 2014. PMID: 24877031
• (2)L(59) TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice.
  Hara M, Inoue I, Yamazaki Y, Kirita A, Matsuura T, Friedman SL, Rifkin DB, Kojima S.
  Fibrogenesis Tissue Repair. 2015 Sep 15;8:17. doi: 10.1186/s13069-015-0034-9. eCollection 2015. PMID: 26379781